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Purpose. To assess whether the diﬀerences in vascular-metabolic relationships between lymphoma masses and colorectal liver
metastases predicted from previous histopathological studies can be demonstrated by dynamic contrast-enhanced CT (DCE-
CT) combined with ﬂuorodeoxyglucose positron emission tomography (FDG-PET). Methods. DCE-CT and FDG-PET studies
were drawn from an imaging archive for patients with either lymphoma masses (n = 11) or hepatic metastases from colorectal
cancer (CRM: n = 12). Tumour vascularity was assessed using DCE-CT measurements of perfusion. Tumour glucose metabolism
was expressed as the mean FDG Standardised Uptake Value (SUVFDG). The relationship between metabolism and vascularity in
each group was assessed from SUVFDG /perfusion ratios and Pearson correlation coeﬃcients. Results.A nS U V FDG threshold of
3.0 was used to designate lymphoma masses as active (AL, n = 6) or inactive lymphoma (IL, n = 5). Tumour perfusion was
signiﬁcantly higher in AL (0.65mL/min/mL) than CRM (0.37mL/min/mL: P = .031) despite similar SUVFDG (5.05 and 5.33,
resp.). AL demonstrated higher perfusion values than IL (0.24mL/min/mL:P = .006).SUVFDG/perfusion was signiﬁcantlyhigher
in CRM (15.3min) than IL (4.2min, P<. 01). There was no correlation between SUVFDG and perfusion for any patient group.
1.Introduction
Theuse ofmultiparametric imagingtostudytherelationship
between vascularisation and metabolism of tumours is
emerging as a topic of interest in oncological imaging [1].
Increased vascularity and increased glucose metabolism are
bothimportant factors inthe growthand metastasis ofmany
tumours[2–8]. Onthe otherhand, poor vascularisation may
lead to hypoxia which is known to contribute to resistance
to radiotherapy and chemotherapy. The degree of vascular-
isation and metabolism represent the ultimate phenotypic
expression of a range of genetic processes occurring within
tumour cells. Imaging the relationship between metabolism
and vascularity can therefore deﬁne tumour phenotypes of
potential prognostic signiﬁcance [9].
Previous studies evaluating the relationship between
tumour metabolism and vascularity have combined ﬂuoro-
18-deoxyglucose positron emission tomography (FDG-
PET) images of metabolism with a range of techniques
that depict tumour vascularity including O-15 water
PET, dynamic contrast-enhanced magnetic resonance and
dynamic contrast-enhanced computed tomography (DCE-
CT) [1]. Of these techniques, DCE-CT is most readily
performed on integrated PET-CT systems remote from a
cyclotron. DCE-CT is increasingly used to evaluate tumour
vascularity on account of the technique’s ability to provide
indirect in vivo assessments of tumour angiogenesis and
oxygenation [10–17]. Tumour perfusion valuesderived from
kinetic analysis of DCE-CT have been validated against a
range of reference methods in animals and man [18–21].
Studies that have compared FDG-PET and DCE-CT in lung,
head and neck, and breast cancers have shown the ability of
combined measurements to demonstrate variations in the
relationship between tumour blood ﬂow and metabolism
within a single tumour type [22–26]. Uncoupling of tumour
perfusion and metabolism has been identiﬁed as a feature
of pulmonary metastases and also larger, more advanced
nonsmall cell lung cancers and cancers of the head and neck2 International Journal of Molecular Imaging
[22, 23]. More recently, a preliminary study has suggested
diﬀerences in vascular-metabolic ratios between grade 2 and
grade 3 breast cancers [25]. However, to date, studies of
tumour metabolism and vascularity have been undertaken
in single tumour types. There have been no studies utilising
F D G - P E Tw i t hD C E - C Tt oe v a l u a t ed i ﬀerences in vascular-
metabolic phenotype between diﬀerent tumours.
Lymphomas are known to exhibit a range of bio-
logical characteristics that diﬀer from those observed in
other tumour types. In particular, immunohistopathological
studies have suggested that Hodgkin’s and Non-Hodgkin’s
lymphomas may be less angiogenic and hypoxically driven
than most solid tumours [26, 27]. Thus, it can be antici-
pated that lymphomas will be unlikely to exhibit hypoxic
stimulation of glucose metabolism seen as low vascularity
on DCE-CT and high glucose metabolism on FDG-PET.
On the other hand, similar studies in colorectal cancer liver
metastases have shown large amounts of hypoxic cells but
with no correlation between the hypoxia marker pimonida-
zole and the expression of the GLUT-1 glucose transporter
[28]. Hence, colorectal metastases would be expected to
show relatively low vascularity (reﬂecting hypoxia) and no
relationship between vascularity and glucose metabolism.
The purpose of this study was to undertake a prelimi-
nary comparison of tumour metabolism and vascularity in
lymphoma masses and colorectal liver metastases to assess
whether the diﬀerences in vascular-metabolic phenotype
predicted from previous histopathological studies can be
demonstrated by combining DCE-CT with FDG-PET. The
ability to demonstrate such intratumoural diﬀerences would
provide further validation of the technique as a means to
characterise the biological behaviour of tumours.
2.Methodsand Materials
2.1. Patients. The study comprised a retrospective review of
imagedataforpatientswithlymphomaandcolorectalcancer
drawn from an imaging archive acquired between 1999 and
2002 as part of a research program evaluating angiogenesis
and glucose metabolism in a range of tumour types. Patients
hadbeenrecruitedsequentially,andall hadundergoneFDG-
PET and CT as part of their clinical care with a single-
location DCE-CT added to the conventional diagnostic CT.
PET and CT examinations had been performed within
48 hours using separate imaging systems. This research
program had been approved by the local ethics committee,
and informed written consent had been obtained from all
patients.
Image data was available for 19 studies in 18 patients
with biopsy-proven lymphoma. Eight studies acquired after
lymphoma therapy were rejected for having no measurable
disease at the anatomical location chosen for DCE-CT. Of
the remaining patients, one had been studied before and
after treatment giving 11 available studies in 10 patients
(7 male, 3 female, median age: 58.1 years, range: 17–
83). The lymphoma subtype had been recorded in the
archive for only 5 patients (2 Hodgkin’s disease, 3 non-
Hodgkin’s lymphoma). Lymphoma studies were classiﬁed as
active or inactive disease on the basis of the FDG uptake
within the lesion on the slice corresponding to the DCE-CT
acquisition.AStandardised UptakeValuefor FDG(SUVFDG)
ofgreaterthan 3.0was consideredtoindicateactive disease, a
threshold value which has previously been shown to predict
a signiﬁcantly poorer progression-free survival [29].
Image data was also available for 40 patients with known
or suspected recurrent colorectal cancer. Five cases were
excluded due to incomplete image data sets, and a further
23 were excluded due to no measurable disease at the
anatomical location chosen for DCE-CT. Thus, 12 patients
were available for analysis, all of which had an FDG-avid
focalliverlesionintheanatomicalslicecorrespondingtothat
chosen for DCE-CT. One patient had been studied before
and after treatment with 5-ﬂuorouracil and levamisole. Only
the pretreatment data was used in this study.
2.2. Positron Emission Tomography. A standard PET imaging
technique had been used for all patients in the archive.
Following a 6-hour fast and conﬁrmation of serum glucose
levelsbelow 10mmoL/L, whole-body PET images of patients
had been acquired 60 minutes after intravenous administra-
tionof120–200MBqFDGusingaGEQUESTdedicatedPET
scanner (GE Medical Systems, Milwaukee, WI). Transmis-
sionscanning hadbeenperformedandattenuationcorrected
images (128x128 pixel, slice thickness of 4mm) produced by
iterative reconstruction using the ordered subset expectation
maximization (OSEM) algorithm. Values for FDG uptake
within the tumour, expressed as the mean Standardised
Uptake Value (SUV), had been determined from the PET
image at the anatomical level corresponding to the DCE-CT
acquisition and recorded within the image archive.
2.3. CT Image Acquisition. The DCE-CT study had been
incorporatedintothepatients’conventionalCTexamination
asfollows:(1)aseriesofunenhancedimageswereacquiredto
determinethe appropriateanatomical levelfor(2)a dynamic
single-location contrast-enhanced sequence followed by (3)
a conventional diagnostic portal phase examination of the
chest, abdomen, and pelvis performed using an additional
100mL bolus of contrast material at least 5 minutes after the
single-location acquisition (CT Twin: Elscint, Haifa, Israel).
Prior to imaging, contrast medium (Ioscan 10mL, sodium
diatrizoate 3.705g; Iotech, Rosebery, Australia) had been
given via mouth following a 4-hour fast.
The single-location DCE-CT sequence of images had
been acquired at the anatomical level containing the largest
transverse dimension of any focal mass lesion identiﬁed
on the unenhanced images. 50mL of conventional contrast
material (Iopamidol, Bracco, Milan) with an iodine concen-
tration of 370mg/mL had been administered intravenously
at 7mL/sec through an 18G cannula. Patients had been
instructed not to take deep breaths but to breathe quietly for
the entire duration of the sequence. Data acquisition started
at the time of contrast material injection. For all patients
apart from3with lymphoma,121-secondimageswithaslice
thickness of 10mm (120kVp, 300mAs) had been obtained
using a cycle time of 3 seconds. For the remaining 3 patients,International Journal of Molecular Imaging 3
60 1-second images had been acquired with a cycle time of
1sec using the same tube voltage but a reduced tube current.
The CT images stored in the archive in Digital Imaging
and Communications in Medicine (DICOM) format were
reanalysed for this study.
2.4. CT Image Analysis. CT analysis was performed by,
or under the supervision of, an operator with 18 years
of experience in perfusion CT imaging (KM) blinded to
the PET ﬁndings. For each patient, a region of interest
(ROI) encompassing the lymphoma mass or liver lesion
was created from the precontrast CT image displayed with
a constant window width and level (300HU and 0HU,
resp.). Further ROIs were created within the aorta and, for
liver lesions, within the spleen. The changes in the X-ray
attenuation within each ROI following administration of
contrast material were displayed as time-attenuation curves
(TACs). For liver lesions, the splenic TAC was used to
determine the time of peak splenic enhancement identifying
the end of the arterial phase. Only arterial phase images (i.e.,
those acquired up to the time of peak splenic enhancement)
were included in the analysis to reﬂect the fact that hepatic
tumours receive their blood supply predominantly from the
hepatic arterial system [30]. Individual images subject to
excessive respiratory motion were eliminated from analysis.
TACs from the three studies acquired with a cycle time of
1 second underwent 3 point temporal smooth to ensure
equivalence with the other studies acquired with a cycle time
of 3 seconds.
Tumour perfusion was calculated as described by Miles
[31] using the following equation:
Tumour perfusion (mL/min/mL)
=
Maximal rate of tumour enhancement (HU/min)
Peak aortic enhancement (HU)
.
(1)
This approach to measuring tumour perfusion has been
validated against thermal clearance and PET using the
steady-state oxygen-15 labelled carbon dioxide method [21].
2.5. Deﬁnition of Vascular-Metabolic Phenotypes. Four
vascular-metabolic phenotypes were deﬁned using the fol-
lowing metabolic-vascular domains categorised by threshold
values for SUVFDG and perfusion: (a) low metabolism/low
perfusion, (b) low metabolism/high perfusion, (c) high
metabolism/high perfusion, and (d) high metabolism/low
perfusion. The threshold value for SUVFDG was 3.0 [29].
As no equivalent perfusion threshold has been determined
previously, the median perfusion value of all included
patients was used.
2.6. Statistical Analysis. The median value and interquar-
tile range were calculated for SUVFDG,p e r f u s i o n ,a n d
SUVFDG/perfusion. Diﬀerences in these parameters between
patient groups (i) active lymphoma (AL), (ii) inactive
lymphoma (IL), and (iii) colorectal cancer liver metastases
(CRM) were tested for signiﬁcance using the Mann-Whitney
test for nonparametric data. Pearson correlation coeﬃcients
were estimated between FDGSUV and perfusion for each
group. The distribution of patients within the four vascular-
m e t a b o l i cp h e n o t y p e sw a st e s t e df o rs i g n i ﬁ c a n c eu s i n g
Fisher’s exact test for a 2 × 2 table. For all statistical tests,
P-values of .05 or less were considered signiﬁcant.
3.Results
Figure 1 comprises examples of conventional CT, perfusion
CT, and FDG-PET images from patients with active lym-
phoma, inactive lymphoma, and colorectal liver metastases.
Tables I(a) and I(b) list the demographics and values of per-
fusion and FDGSUV for each patient with active lymphoma,
inactive lymphoma, and colorectal liver metastases. Pairwise
comparisons of patient groups showed tumour perfusion
was signiﬁcantly higher in AL (0.65 mL/min/mL) than
CRM (0.37mL/min/mL: P = .031) despite similar SUVFDG
(5.05 and 5.33, resp.). Active lymphoma masses demon-
strated higher perfusion values than inactive lymphoma
(0.24mL/min/mL: P = .006). The SUVFDG /perfusion ratio
was signiﬁcantly higher in CRM (15.3min) than IL (4.2min,
P<. 01). Refer to Table 2 and Figure 3.
Figure 2 displays the relationships between FDGSUV
and perfusion for the three patient groups. Linear regres-
sion analysis showed no statistically signiﬁcant correla-
tion between these two parameters for any patient group.
The distribution of cases within the metabolic-vascular
domains based on thresholds of ≥3.0 for SUVFDG and
the median perfusion value of all cases (≥0.4mL/min/mL)
was signiﬁcantly non-random (P<. 00005), All cases of
IL fell within the low metabolism/low perfusion domain
whereas all cases of AL exhibited high metabolism and
high perfusion. Colorectal liver metastases were evenly
distributed between high metabolism/high perfusion and
high metabolism/low perfusion domains. No cases were
classiﬁed as low metabolism/high perfusion.
4.Discussion
Our results conﬁrm that combined FDG-PET and DCE-CT
has thepotentialtoevaluatevascular-metabolic relationships
in lymphoma and colorectal liver metastases. The diﬀerences
between active lymphoma and colorectal liver metastases
demonstrated by this imaging approach are consistent with
previously reported histopathological studies.
Our main ﬁnding was that, although active lymphoma
and colorectal liver metastases exhibited similar levels of
metabolism, there were signiﬁcant diﬀerences in perfusion
between these tumour types. In view of the previously
demonstrated correlation between CT perfusion measure-
ments and tumour oxygenation [16], our main ﬁnding
corresponds to previous immunohistochemical studies indi-
cating that hypoxia is uncommon in lymphoma but is
a prominent feature in colorectal liver metastases [26–
28]. However, it is also interesting that colorectal liver
metastases with low perfusion tended to exhibit SUVFDG
no higher than either colorectal liver metastases with high4 International Journal of Molecular Imaging
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CT Perfusion CT FDG-PET
(c)
Figure 1: Conventional CT (left column), perfusion CT (middle column), and FDG-PET (right column) images of patients with (a) active
lymphoma,(b) inactive lymphoma,and(c) colorectal liver metastases.Arrows indicate the tumour masses.Active lymphoma demonstrated
high blood ﬂow and high FDG uptake, inactive lymphoma, low blood ﬂow and low FDG uptake, whilst the colorectal liver metastasis
demonstrates low blood ﬂow and high glucose metabolism.
perfusion or active lymphoma. This latter ﬁnding is in
contrast to previous studies in nonsmall lung cancer and
head and neck tumours which have shown that low levels
of tumour vascularity are often associated with particularly
high levels of glucose metabolism [22, 23]. Hypoxia is a
recognisedstimulusforincreasedglucosemetabolism, which
can be considered as an adaptive response to hypoxia [32].
Our ﬁnding of comparable metabolism in high and low
perfusion in colorectal liver metastases suggests a failure of
adaptation to hypoxia in this tumour type. This ﬁnding
is also consistent with published results of histochem-
ical analysis of colorectal liver metastases which found
no correlation between the hypoxia marker pimonidazole
and the expression of the GLUT-1 glucose transporter
[28].
To our knowledge, this is the ﬁrst study to use FDG-
PET and DCE-CT to compare the relationship between
vascularity and metabolism in diﬀerent tumour types. How-
ever, the relationships between perfusion and metabolism in
lymphoma and colorectallivermetastases have been assessed
previously in separate studies [33, 34]. Dimitrakopoulou-
Strauss et al. used PET measurements of SUV for oxygen-15
water (SUVwater) and FDG to assess tumour perfusion and
metabolism in patients with malignant lymphomas before
and after treatment, and they reported a nonlinear corre-
lation between these two parameters [33]. This contrasts
with our study in that no correlation between perfusion and
metabolism was observed in patients with either active or
inactive lymphoma. Nevertheless, 5 minute after injection,
SUVwater measurements may not be directly equivalent to
absolute measurements of perfusion. Amongst our patients,
all cases of inactive lymphoma had perfusion values of less
than 0.4mL/min/mL. This threshold value is higher than the
0.2mL/min/mL value previously proposed by Dugdale et al.
[35]. Unlike our study, the series of Dugdale et al. did not
classify disease activity on the basis of FDG-PET. We found
no overlap in perfusion values between active and inactive
cases suggesting that, for lymphoma masses, perfusion andInternational Journal of Molecular Imaging 5
Table 1
(a) Demographics and imaging results for patients with lymphoma.
(N = non-Hodgkin’s lymphoma, H = Hodgkin’s disease).
Tumour type Age
(years)/sex FDG SUV Blood ﬂow
(mL/min/mL)
Active
lymphomaN 65/M 3.5 0.99
Active lymphoma 71/F 5.0 0.58
Active lymphoma 40/F 5.0 0.7
Active
lymphomaH 62/M 5.1 1.01
Active
lymphomaN 56/M 6.5 0.6
Active lymphoma 83/M 11.9 0.4
Median
(Interquartile
range)
64 (57–69) 5.0 (5.0–6.1) 0.65 (0.59–0.92)
Inactive
lymphomaN 40/F 1 0.24
Inactive
lymphoma 51/M 1 0.1
Inactive
lymphoma 58/M 1.2 0.32
Inactive
lymphomaH 17/F 1.5 0.37
Inactive
lymphomaN 77/M 1.6 0.24
Median
(Interquartile
range)
51 (40–58) 1.2 (1.0–1.5) 0.24 (0.24–0.32)
(b) Demographics and imaging results for patientswith colorectal liver
metastases.
Tumour type Age/sex FDG SUV Blood ﬂow
(mL/min/mL)
Colorectal cancer 73/F 5.5 0.15
Colorectal cancer 49/M 5.5 1.04
Colorectal cancer 58/F 3.8 0.43
Colorectal cancer 52/F 5.3 0.57
Colorectal cancer 64/M 6.9 0.49
Colorectal cancer 73/M 4.8 0.26
Colorectal cancer 75/F 4.1 0.16
Colorectal cancer 56/F 5.8 0.57
Colorectal cancer 50/M 5.1 0.13
Colorectal cancer 72/M 5.2 0.16
Colorectal cancer 65/M 5.3 0.64
Colorectal cancer 87/F 6.1 0.37
Median
(Interquartile range)
65
(55–73) 5.3 (5.0–5.6) 0.37 (0.16–0.57)
SUVFDG values may provide similar information. Larger
trials would be needed to conﬁrm this ﬁnding.
Fukuda et al. used oxygen-15 water measurements and
FDG-PET to study perfusion and metabolism in liver
Table 2: Prevalence of tumour type in each metabolic-vascularity
domain (hypometabolic: SUV < 3, hypovascular: perfusion <
0.4mL/min/mL,P<. 00005, Fisher’s exact test).
Inactive
lymphoma
Active
lymphoma
Colorectal liver
metastases
Hypometabolic/
hypovascular 500
Hypermetabolic/
hypervascular 066
Hypermetabolic/
hypovascular 006
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Figure 2: Relationships between FDG Standardised Uptake Value
(SUV) and blood ﬂow for active lymphoma, inactive lymphoma,
and colorectal liver metastases.
tumours including six colorectal liver metastases [34]. The
median values for perfusion and FDGSUV in that study
(0.32mL/min/mL and 4.6, resp.) were very similar to those
in our patient group (0.37mL/min/mL and 5.3, resp.).
Both studies also found no correlation between tumour
metabolism and perfusion in colorectal liver metastases,
implyingthattheseparametersprovidediﬀerentinformation
about the biological status of such tumours and highlighting
the potential for combined DCE-CT/FDG-PET to provide
distinctive information about tumour biology.
The two previous studies of perfusion and metabolism
in lymphoma and colorectal liver metastases both used
oxygen-15 water PET rather than DCE-CT to assess tumour
vascularity. There are important diﬀerences between these
two techniques. Oxygen-15 water is a diﬀusible tracer that
will more closely reﬂect the delivery of nutrients to tumour
tissue. The presence of arteriovenous shunts will not aﬀect
oxygen-15 water measurements of perfusion but will con-
tributeto perfusion valuesobtainedwith DCE-CT.Although
not contributing to the delivery of nutrients to tumour
tissue, arteriovenous shunts are an important pathological
feature that distinguishes tumour vascularisation from the
vascularisation of normal tissues. Thus, by capturing the
eﬀects of arteriovenous shunting, DCE-CTmeasurements of6 International Journal of Molecular Imaging
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Figure 3: Prevalence of tumour type in each metabolic-vascular
domain (hypometabolic: SUV < 3, hypovascular: perfusion
<0.4mL/min/mL,P<. 00005, Fisher’s exact test).
perfusion will depict an aspect of tumour vascularity not
detected by oxygen-15 water PET. The use of DCE-CT can
also avoid some of the artefacts that may occur with oxygen-
15 water PET such as spill over of counts from adjacent
vascular structure which may be an important consideration
for assessing lymphoma masses which are frequently located
close to the aorta and mesenteric vessels. Notwithstanding
these theoretical diﬀerences, our DCE-CT measurements of
perfusion with CRM were comparable to those reported by
Naumann et al. and recent comparative study of oxygen-
15 water PET and DCE-CT measurements of perfusion in
solid tumours found a good correlation between the two
techniques [29].
Our study identiﬁed threshold values for SUVFDG
(≥3.0) and perfusion (≥0.4mL/min/mL) deﬁning vascular-
metabolic domains that eﬀectively distinguished the three
patients groups (active lymphoma, inactive lymphoma, and
colorectal liver metastases). Increased glucose metabolism
is a fundamental property of tumour cells whereas the
new vessels resulting from angiogenesis are predominantly
derived from the surrounding native vascular system. Thus,
identiﬁcation of speciﬁc vascular-metabolic domains may
be able to classify tumours on the basis of the biological
behaviour of the tumour itself and the host’s response to
the tumour. Clinical studies in a range of tumour types
have shown variable and inconsistent relationships between
tumour perfusion and metabolism [1, 22–24, 33, 34, 36–40].
High metabolism with low vascularity has previously been
demonstrated in larger, more advanced tumours, [22, 36]
and adjacent to areas of necrosis [27, 28]. Furthermore,
mismatching of tumour perfusion and metabolism may also
be induced by cancer therapy, particularly drugs that target
the tumour vasculature [41, 42]. Our study has shown that
perfusion-metabolic mismatch is also common in colorectal
liver metastases.
An important limitation of our study is the retrospective
analysis ofa relative small number ofpatients drawn from an
imaging archive with incomplete clinical data. Furthermore,
improvements of DCE-CT technique and PET technology
have occurred since the creation of the archive. For example,
a lower tube-voltage (80–100kVp) is now recommended
for DCE-CT than that widely adopted at the time our
cases were acquired, and the increased axial ﬁeld of view
of current CT systems allows study of greater tissue volume
withthepotentialtoreducetheimpact ofbreathingartefacts.
Nevertheless, the increasing use of contrast agent during
clinical PET-CT [43, 44] will allow DCE-CT and FDG-PET
to be combined in a single examination and so facilitate the
larger prospective studies that are needed to conﬁrm our
ﬁndings and to evaluate the potential for combined param-
eters of perfusion and FDG uptake to provide prognostic
information.
The potential clinical implications of our study are
diﬀerent for lymphoma and colorectal liver metastases. For
lymphoma, if the apparent equivalence of FDG-PET and
DCE-CT for assessing disease activity is conﬁrmed in larger
trials, it is possible that DCE-CT could become a feasible
technique for a preliminary assessment of residual lym-
phoma masses on completion of chemotherapy. Perfusion
values remaining above 0.4mL/min/mL could potentially
be used to select patients for consolidation therapy. On
the other hand, the inability of DCE-CT to image multiple
tumoursiteswould preventthewithholding ofconsolidation
therapy on the basis of a low perfusion value in a single
targetlymphomamassbecauseresidualdiseaseactivitycould
be present in other lesions not assessed by DCE-CT. For
colorectal liver metastases, it is feasible that combined FDG-
PET/DCE-CTcouldbe usedtoclassify liverlesions in a novel
way on the basis of their vascular-metabolic domain. Metas-
tases exhibiting high metabolism/high perfusion may have
ad i ﬀerent prognosis from those with high metabolism/low
perfusion. Thispotentialprognosticvalueissuggestedbytwo
previous studies that have used either FDG-PET or DCE-
CT in separate series of patients with hepatic metastases.
These studies suggest that high glucose metabolism and low
perfusion in CRM are both associated with reduced survival
[45]. However, studies that combine imaging with clinical
followup are needed to conﬁrm the potential prognostic
value of this combined technique.
In summary, this preliminary study has demonstrated
the potential for combined FDG-PET and DCE-CT to
demonstrate diﬀerences in vascular-metabolic relationships
in lymphoma and colorectal liver metastases. The diﬀer-
ences shown are consistent with the ﬁndings of previous
histopathological studies. The higher perfusion values found
in active lymphoma compared to colorectal liver metastases
areconsistentwithahigherincidenceofhypoxiaincolorectal
liver metastases. However, this reduction in blood ﬂow
was not associated with a greater SUVFDG, suggesting poor
adaptation to hypoxia in this tumour type.International Journal of Molecular Imaging 7
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